A new antibody called E06 IgG reduced harmful oxidized fats in artery plaques by 29 percent and decreased immune cell buildup by 28 percent in mice with heart disease, according to Gram Research analysis. The treatment worked by directly targeting damaging molecules inside plaques rather than lowering blood cholesterol, suggesting a new approach to fighting atherosclerosis that complements existing therapies.
Researchers tested a new antibody treatment called E06 IgG that targets harmful oxidized fats in artery plaques. In a study with mice prone to heart disease, the treatment reduced the buildup of damaging molecules and immune cells inside plaques by about one-third. While the treatment didn’t lower overall cholesterol levels, it showed promise as a targeted approach to fight atherosclerosis by attacking the problem directly where it happens: inside artery walls. This research suggests a new way to treat heart disease that works differently from traditional cholesterol-lowering drugs.
Key Statistics
A 2026 research study in mice found that E06 IgG antibody treatment reduced harmful oxidized phospholipids in artery plaques from 28.5 percent to 20.1 percent of plaque material, representing a 29 percent reduction in lesional PC-OxPL.
According to research reviewed by Gram, E06 IgG treatment decreased macrophage immune cell accumulation in plaques from 47.6 percent to 34.3 percent of lesion area, a 28 percent reduction that may reduce plaque inflammation.
A 2026 study in cholesterol-fed mice demonstrated that E06 IgG selectively neutralized oxidized fats inside artery plaques but produced only transient changes in circulating oxidized fats measured in the bloodstream.
The Quick Take
- What they studied: Whether an antibody called E06 IgG could reduce harmful oxidized fats and inflammation inside artery plaques in mice with high cholesterol
- Who participated: Male mice genetically engineered to develop heart disease (Ldlr-/- mice) that were fed a high-cholesterol diet. Mice received either a placebo or E06 IgG treatment at two different doses for 12 weeks
- Key finding: E06 IgG treatment reduced harmful oxidized phospholipids in plaques by about 36 percent and decreased immune cell buildup in plaques by about 28 percent compared to placebo, though it did not change blood cholesterol levels
- What it means for you: This research suggests a new type of heart disease treatment that works by directly targeting the damaging molecules inside artery plaques rather than just lowering cholesterol. However, this is early-stage research in mice, and much more testing is needed before any human treatments could be developed
The Research Details
Researchers used mice that are genetically prone to developing heart disease and fed them a high-cholesterol diet to speed up plaque formation. The mice were divided into three groups: one received a placebo injection, one received a lower dose of E06 IgG (5 mg/kg), and one received a higher dose (25 mg/kg). Both treatment groups received injections twice per week for 12 weeks.
After 12 weeks, the researchers examined the plaques that had formed in the mice’s arteries. They measured how much of the harmful oxidized fat (called PC-OxPL) was present in the plaques, how many immune cells had accumulated there, and whether the plaques had changed in size or structure. They also checked blood samples to see if the treatment affected cholesterol levels or circulating oxidized fats.
In a second experiment, researchers gave mice a single injection of E06 IgG and tracked how long the antibody stayed in the bloodstream and whether it affected circulating oxidized fats over time.
This study design is important because it tests whether E06 IgG works by directly neutralizing harmful oxidized fats inside plaques versus simply removing them from the bloodstream. Understanding where and how the treatment works helps researchers design better therapies. The study also shows whether this approach might work alongside or instead of traditional cholesterol-lowering drugs
The study used multiple measurement techniques to verify results, including specialized mass spectrometry to measure oxidized fats. The researchers tested two different doses to see if higher amounts produced better results. However, this is animal research in mice, which don’t always respond the same way humans do. The study was relatively short (12 weeks), so long-term effects are unknown. The sample size for the mouse groups was not specified in the abstract
What the Results Show
E06 IgG treatment successfully reduced the amount of harmful oxidized phospholipids inside artery plaques. In the placebo group, these harmful molecules made up 28.5 percent of the plaque material, while in mice receiving the higher dose of E06 IgG, this dropped to 20.1 percent. This represents about a 29 percent reduction in the harmful oxidized fats where they cause the most damage.
The treatment also reduced the number of immune cells (macrophages) that accumulate inside plaques. These immune cells contribute to inflammation and plaque instability. Placebo-treated mice had 47.6 percent macrophages in their plaques, while treated mice had about 34 percent, a reduction of roughly 28 percent.
Interestingly, the treatment did not significantly change overall cholesterol levels in the blood, nor did it reduce the total size of the plaques that formed. This suggests E06 IgG works by modifying what’s inside existing plaques rather than preventing new plaque formation or lowering cholesterol.
When researchers gave mice a single injection of E06 IgG and tracked circulating oxidized fats in the blood, they found only temporary, minor changes. This suggests the antibody primarily works inside artery walls rather than removing oxidized fats from the bloodstream. The antibody did successfully reach its target in the blood (showing target engagement), but this didn’t translate to sustained reductions in circulating oxidized fats measured by two different laboratory methods
Previous research showed that mice genetically engineered to produce E06 antibodies had less atherosclerosis. This new study tests whether giving the antibody as a treatment (passive immunization) could achieve similar benefits. The results support the earlier findings but reveal important differences: the antibody works locally in plaques rather than systemically in the blood. This finding challenges the assumption that reducing circulating oxidized fats is necessary for therapeutic benefit
This research was conducted only in mice, which have different immune systems and metabolism than humans. The study lasted only 12 weeks, so long-term effects and safety are unknown. The treatment did not reduce plaque size or change blood cholesterol, which are important clinical outcomes. The exact number of mice in each group was not provided. The study did not test whether the treatment could stabilize existing plaques or prevent heart attacks. Human trials would be needed to determine if these results apply to people with heart disease
The Bottom Line
This research provides proof-of-concept that targeting oxidized fats inside plaques is a viable approach to treating atherosclerosis. However, these are early findings in mice. Current evidence does not support using E06 IgG in humans yet. People with heart disease should continue following their doctor’s advice about cholesterol-lowering medications and lifestyle changes. This research may eventually lead to new treatment options, but that is years away. Confidence level: Low to moderate for future human applications; this is foundational research
This research is most relevant to cardiologists, researchers studying atherosclerosis, and pharmaceutical companies developing new heart disease treatments. People with existing heart disease or high cholesterol should be aware of this research direction but should not expect new treatments based on this work in the near future. This research does not change current treatment recommendations
If E06 IgG or similar treatments move forward, human clinical trials would likely take 5 to 10 years minimum. Even if successful in trials, regulatory approval and availability could take several more years. This is very early-stage research, so realistic timelines for any human application are measured in years, not months
Frequently Asked Questions
What is E06 IgG and how does it treat heart disease?
E06 IgG is an antibody that targets oxidized phospholipids, harmful molecules that accumulate in artery plaques. In mice, it reduced these damaging molecules by 29 percent and decreased immune cell buildup by 28 percent, working directly inside plaques rather than lowering blood cholesterol
Does E06 IgG lower cholesterol levels?
No, E06 IgG did not significantly reduce blood cholesterol levels in the mouse study. Instead, it works by neutralizing harmful oxidized fats already present inside artery plaques, suggesting a different mechanism than traditional cholesterol-lowering drugs
When will E06 IgG be available as a treatment for humans?
E06 IgG is not yet available for human use. This is early-stage research in mice. If development continues, human clinical trials would likely take 5 to 10 years minimum, with regulatory approval potentially taking several additional years
Can I use E06 IgG instead of my cholesterol medication?
No, E06 IgG is not approved for human use and is only being studied in laboratory mice. Continue taking cholesterol medications prescribed by your doctor. Discuss any new heart disease treatments with your healthcare provider before making changes
How does E06 IgG differ from current heart disease treatments?
Current treatments mainly lower cholesterol in the blood. E06 IgG targets oxidized fats specifically inside artery plaques and reduces inflammation there, offering a potentially complementary approach that works through a different mechanism than existing medications
Want to Apply This Research?
- Users interested in heart health could track their weekly cholesterol levels, blood pressure readings, and any new medications prescribed by their doctor. This creates a baseline for monitoring cardiovascular health while emerging therapies like E06 IgG are being developed
- Users could set reminders to take their current heart disease medications as prescribed, track adherence to cholesterol-lowering drugs, and log lifestyle factors like exercise minutes and dietary choices. This maintains current treatment effectiveness while new therapies are being researched
- Establish a long-term tracking system for annual cholesterol panels, blood pressure trends, and medication changes. Users could also note any new heart disease treatments their doctor mentions, creating a personal record of emerging therapies they might discuss with their healthcare provider in future appointments
This research describes early-stage laboratory findings in mice and does not represent approved human treatments. E06 IgG is not available for human use. People with heart disease should continue following their doctor’s treatment recommendations and not delay or change current medications based on this research. Consult with a healthcare provider before making any changes to heart disease treatment or prevention strategies. This article is for educational purposes and should not be considered medical advice
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.